Skip to main content
SpringerLink
Log in

Adalimumab

Lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Tadros J, et al. 28463 Aprelimast and psoriasis: Significant hemoglobin A1c reduction and improved insulin resistance independent of changes in body mass index. Journal of the American Academy of Dermatology 85 (Suppl.): AB192 abstr. 28463, No. 3, Sep 2021. Available from: URL: http://doi.org/10.1016/j.jaad.2021.06.780 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab. Reactions Weekly 1870, 17 (2021). https://doi.org/10.1007/s40278-021-01227-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-01227-0

Search

Navigation